AU2001289145A1 - Monoclonal antibody ds6, tumor-associated antigen ca6, and methods of use thereof - Google Patents

Monoclonal antibody ds6, tumor-associated antigen ca6, and methods of use thereof

Info

Publication number
AU2001289145A1
AU2001289145A1 AU2001289145A AU8914501A AU2001289145A1 AU 2001289145 A1 AU2001289145 A1 AU 2001289145A1 AU 2001289145 A AU2001289145 A AU 2001289145A AU 8914501 A AU8914501 A AU 8914501A AU 2001289145 A1 AU2001289145 A1 AU 2001289145A1
Authority
AU
Australia
Prior art keywords
tumor
methods
monoclonal antibody
associated antigen
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001289145A
Other languages
English (en)
Inventor
Diane A. Semer
Anne Elizabeth Wennerberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
East Carolina University
Original Assignee
University of North Carolina at Chapel Hill
East Carolina University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of North Carolina at Chapel Hill, East Carolina University filed Critical University of North Carolina at Chapel Hill
Publication of AU2001289145A1 publication Critical patent/AU2001289145A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2001289145A 2000-08-18 2001-08-17 Monoclonal antibody ds6, tumor-associated antigen ca6, and methods of use thereof Abandoned AU2001289145A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09641499 2000-08-18
US09/641,499 US6596503B1 (en) 2000-08-18 2000-08-18 Monoclonal antibody DS6, tumor-associated antigen CA6, and methods of use thereof
PCT/US2001/041765 WO2002016401A2 (fr) 2000-08-18 2001-08-17 Anticorps monoclonal ds6 et ses procedes d'utilisation

Publications (1)

Publication Number Publication Date
AU2001289145A1 true AU2001289145A1 (en) 2002-03-04

Family

ID=24572648

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001289145A Abandoned AU2001289145A1 (en) 2000-08-18 2001-08-17 Monoclonal antibody ds6, tumor-associated antigen ca6, and methods of use thereof

Country Status (7)

Country Link
US (5) US6596503B1 (fr)
EP (1) EP1362060A4 (fr)
AU (1) AU2001289145A1 (fr)
CA (1) CA2419270C (fr)
GB (1) GB2383331B (fr)
MX (2) MX347883B (fr)
WO (1) WO2002016401A2 (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
KR101424624B1 (ko) 2003-05-14 2014-07-31 이뮤노젠 아이엔씨 약물 콘쥬게이트 조성물
US20050123549A1 (en) * 2003-07-21 2005-06-09 Immunogen Inc. CA6 antigen-specific cytotoxic conjugate and methods of using the same
AU2012201260B2 (en) * 2003-07-21 2014-10-23 Immunogen, Inc. A CA6 antigen-specific cytotoxic conjugate and methods of using the same
US7834155B2 (en) 2003-07-21 2010-11-16 Immunogen Inc. CA6 antigen-specific cytotoxic conjugate and methods of using the same
JP2007529201A (ja) * 2004-03-11 2007-10-25 シャーンタ ウェスト インコーポレーティッド Ｒｍ１抗原の治療目的使用方法
EP1853322B1 (fr) 2005-02-11 2014-06-25 ImmunoGen, Inc. Procédé pour préparer des conjugués d'anticorps et de maytansinoïdes
KR101566393B1 (ko) 2005-08-03 2015-11-05 이뮤노젠 아이엔씨 면역접합체 제형
EA020130B9 (ru) * 2005-08-22 2014-10-30 Иммьюноджен, Инк. Специфичное к антигену са6 антитело, содержащий его цитотоксический конъюгат и способы применения конъюгата
CN104804094A (zh) * 2005-08-22 2015-07-29 伊缪诺金公司 Ca6抗原特异性细胞毒性偶联物及其应用方法
AU2006283726C1 (en) 2005-08-24 2015-05-07 Immunogen, Inc. Process for preparing maytansinoid antibody conjugates
WO2007127160A2 (fr) * 2006-04-24 2007-11-08 Shantha West, Inc. Antigène agrm2
WO2008152446A2 (fr) 2006-11-27 2008-12-18 Patrys Limited Nouvelle cible de peptide glycosylé dans des cellules néoplasiques
US8012678B2 (en) * 2007-07-24 2011-09-06 Wisconsin Alumni Research Foundation Biomarkers for human papilloma virus-associated cancer
KR20220035504A (ko) 2008-04-30 2022-03-22 이뮤노젠 아이엔씨 가교제 및 그 용도
CA2728347A1 (fr) 2008-06-16 2010-01-14 Patrys Limited Anticorps anti-lm, fragments fonctionnels, antigene cible lm-1, et procedes pour les preparer et les utiliser
US10359425B2 (en) 2008-09-09 2019-07-23 Somalogic, Inc. Lung cancer biomarkers and uses thereof
ES2559758T3 (es) * 2008-09-09 2016-02-15 Somalogic, Inc. Biomarcadores de cáncer de pulmón y usos de los mismos
SG10201810743WA (en) 2009-06-03 2018-12-28 Immunogen Inc Conjugation methods
EP2486023A4 (fr) 2009-10-06 2014-05-07 Immunogen Inc Conjugués puissants et séquences de liaison hydrophiles
BR112012032537B8 (pt) * 2010-07-09 2022-10-18 Somalogic Inc Métodos para diagnosticar se um indivíduo tem ou não câncer de pulmão de não pequenas células, ou para fornecer informações sobre câncer de pulmão de não pequenas células em um indivíduo
US20120040861A1 (en) 2010-08-13 2012-02-16 Somalogic, Inc. Pancreatic Cancer Biomarkers and Uses Thereof
SI2691155T1 (sl) 2011-03-29 2019-03-29 Immunogen, Inc. Priprava majtanzinoidnih konjugatov protiteles v postopku z enim korakom
SG193997A1 (en) 2011-03-29 2013-11-29 Immunogen Inc Process for manufacturing conjugates of improved homogeneity
CA3064363C (fr) * 2011-10-24 2022-05-17 Somalogic, Inc. Biomarqueurs de cancer du poumon a cellule non petite
CA2852709A1 (fr) 2011-10-28 2013-05-02 Patrys Limited Epitopes pat-lm1 et leurs procedes d'utilisation
JP2012161321A (ja) * 2012-03-30 2012-08-30 Immunogen Inc Ｃａ６抗原特異的細胞傷害性コンジュゲート、および該コンジュゲートを用いる方法
SG10201702737TA (en) 2012-10-04 2017-05-30 Immunogen Inc Use of a pvdf membrane to purify cell-binding agent cytotoxic agent conjugates
US9989524B2 (en) * 2013-02-05 2018-06-05 Sanofi Immuno imaging agent for use with antibody-drug conjugate therapy
US9844607B2 (en) 2013-02-05 2017-12-19 Sanofi Immuno imaging agent for use with antibody-drug conjugate therapy
US10413615B2 (en) 2014-11-19 2019-09-17 Immunogen, Inc. Process for preparing cell-binding agent-cytotoxic agent conjugates
EP3411077A1 (fr) 2016-02-05 2018-12-12 ImmunoGen, Inc. Procédé efficace de préparation de conjugués agent de liaison cellulaire-agent cytotoxique
WO2017194568A1 (fr) 2016-05-11 2017-11-16 Sanofi Schéma de traitement utilisant un anticorps immunoconjugué anti-muc1 à base de maytansinoïde pour le traitement des tumeurs

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4931385A (en) * 1985-06-24 1990-06-05 Hygeia Sciences, Incorporated Enzyme immunoassays and immunologic reagents
US5366866A (en) 1991-07-25 1994-11-22 Duke University Method of diagnosing ovarian and endometrial cancer with monoclonal antibodies OXA and OXB
WO1994021294A1 (fr) 1993-03-19 1994-09-29 Bigner Darell D Procede de traitement de tumeurs a l'aide d'anticorps
AU6445894A (en) 1993-03-19 1994-10-11 Duke University Method of treatment of tumors with an antibody binding to tenascin
US5871941A (en) 1995-07-28 1999-02-16 Univ British Columbia Method of testing expression of CA125 antigen in cultured ovarian surface epithelial cells to identify and monitor individuals having a predisposition to develop ovarian cancer
US7037667B1 (en) * 1998-06-01 2006-05-02 Agensys, Inc. Tumor antigen useful in diagnosis and therapy of prostate and colon cancer
US7834155B2 (en) * 2003-07-21 2010-11-16 Immunogen Inc. CA6 antigen-specific cytotoxic conjugate and methods of using the same
US20050123549A1 (en) 2003-07-21 2005-06-09 Immunogen Inc. CA6 antigen-specific cytotoxic conjugate and methods of using the same

Also Published As

Publication number Publication date
WO2002016401A2 (fr) 2002-02-28
CA2419270C (fr) 2013-05-14
US20030215895A1 (en) 2003-11-20
US7507410B2 (en) 2009-03-24
US20070196276A1 (en) 2007-08-23
US20090155930A1 (en) 2009-06-18
GB2383331B (en) 2004-09-29
GB2383331A (en) 2003-06-25
WO2002016401A3 (fr) 2002-04-11
EP1362060A4 (fr) 2004-09-08
US6596503B1 (en) 2003-07-22
US20120045776A1 (en) 2012-02-23
US8067186B2 (en) 2011-11-29
CA2419270A1 (fr) 2002-02-28
GB0306083D0 (en) 2003-04-23
US7351805B2 (en) 2008-04-01
MX347883B (es) 2017-05-16
US8728741B2 (en) 2014-05-20
EP1362060A2 (fr) 2003-11-19
MXPA03001460A (es) 2004-12-13

Similar Documents

Publication Publication Date Title
AU2001289145A1 (en) Monoclonal antibody ds6, tumor-associated antigen ca6, and methods of use thereof
AU2001268855A1 (en) Single-domain antigen-binding antibody fragments derived from llama antibodies
AU2002338015A1 (en) Human CDR-grafted antibodies and antibody fragments thereof
AU2002220843A1 (en) Humanised antibodies and uses thereof
AU2559799A (en) Antibody fragment-polymer conjugates and humanized anti-il-8 monoclonal antibodies and uses of same
AU2002327704A1 (en) Antibodies that bind to cancer-associated antigen cytokeratin 8 and methods of use thereof
AU2002244968A1 (en) Anti-osteopontin antibody and use thereof
IL206832A0 (en) Antibodies binding an 161p2f10b epitope and uses thereof
AU2001256325A1 (en) Human and humanized fap-alpha-specific antibodies
AU2001218871A1 (en) Monoclonal antibody and method and kit for the immunoassay of soluble human st2 with the use of the same
AU2002340167A1 (en) Anti-hla-dr antibodies and the methods of using thereof
EP1581096A3 (fr) Antigene pipa et anticorps de liaison a celui-ci
EP1581096A4 (fr) Antigene pipa et anticorps de liaison a celui-ci
AU2002305478A1 (en) Conjugates of reduced antibodies and biomolecules
AU2003260513A1 (en) Polyclonal antibodies, preparation method thereof and use of same
AU2002217212A1 (en) Method for preparing a human monoclonal antibody, fragments thereof or antibodies comprising such fragments, resulting antibodies and use thereof
IL158846A0 (en) A variable region of the monoclonal antibody against the hbv s-surface antigen and a gene encoding the same
AU2003244237A1 (en) Monoclonal antibody against adiponectin, preparation method and use thereof
AU2001284899A1 (en) Methods and universal monoclonal antibody array
AU2002227272A1 (en) Ovarian tumor antigen and methods of use therefor
AU2001261534A1 (en) The meca-79 antigen and related methods
AU2002340850A1 (en) Antigen mimotopes and vaccine against cancers
AU2003211292A1 (en) Monoclonal antibody against human hepatoma and use thereof
AU2002355942A1 (en) Monoclonal antibodies against fungi and methods for their use
AU2003232907A1 (en) Immunogenic, monoclonal antibody comprising at least 2 different epitopes of a tumor-associated antigen